VO - Vanguard Mid-Cap ETF

NYSEArca - Nasdaq Real Time Price. Currency in USD
-0.3804 (-0.2369%)
As of 11:03AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close160.6000
Bid160.2700 x 300
Ask160.3200 x 200
Day's Range160.0864 - 160.6600
52 Week Range133.3800 - 161.3800
Avg. Volume364,374
Net Assets94.73B
PE Ratio (TTM)N/A
YTD Return19.27%
Beta (3y)0.99
Expense Ratio (net)0.06%
Inception Date2004-01-26
Trade prices are not sourced from all markets
  • Hot Areas of Last Week and Their ETFs
    Zacks4 months ago

    Hot Areas of Last Week and Their ETFs

    Hopes for Trump's tax reforms, abating North Korea fears, lower-than-expected damage from Hurricane Irma and record stock market highs rekindled the love for U.S. equity ETFs last week.

  • ETF.com4 months ago

    Least Popular ETFs Of The Year

    It may be surprising to hear that in a year in which ETFs are shattering all sorts of records with regard to the amount of money they are taking in, the world's largest exchange-traded fund isn't participating in the bonanza. That's right; the SPDR S&P 500 ETF Trust (SPY), the $242 billion behemoth, has actually had net outflows this year to the tune of $4.2 billion.

  • Market Realist5 months ago

    How Jazz Pharmaceuticals Aims to Boost Vyxeos Sales in 2017

    In early 2017, Jazz Pharmaceuticals (JAZZ) expanded its sales force team from 35 to 55 and expanded its field reimbursement teams to support the commercial launch of Vyxeos in the US.

  • Market Realist5 months ago

    Inside the Efficacy of JAZZ’s JZP-110 in Obstructive Sleep Apnea Trials

    This trial demonstrated the efficacy and safety of JAZZ's JZP-110 in both the MWT and sleep latency tests at all dosages at the end of weeks 4 and 12.

  • Market Realist5 months ago

    Erwinaze Sales May Remain Flat in 2017

    Erwinaze saw net sales worth $49 million in 2Q17, almost flat compared to the drug’s revenues of $50 million in 2Q16.

  • Market Realist5 months ago

    Dental and Healthcare Consumables Grew but Missed Expectations in 2Q17

    In 2Q17, Dentsply Sirona’s (XRAY) Dental and Healthcare Consumables business contributed ~56% to the company’s total revenues and registered sales of ~$554 million.

  • Market Realist5 months ago

    Align Technology Focuses on International Market Strategy

    In 2Q17, Align Technology (ALGN) reported 85,400 Invisalign case shipments in international markets, which is YoY (year-over-year) growth of ~37.4% and sequential growth of ~13.6%. This growth was mainly ...

  • Market Realist6 months ago

    Edwards Lifesciences’ Mitral Regurgitation Segment

    To diversify its focus beyond aortic structural heart conditions, Edwards Lifesciences (EW) acquired CardiAQ Valve Technologies in August 2015.

  • Market Realist6 months ago

    Can Edwards Lifesciences See Robust Net Profit Margin in 2017?

    In its 2Q17 earnings conference call, Edwards Lifesciences (EW) projected 2017 adjusted EPS to fall to $3.65–$3.85, which is higher than the previous $3.43–$3.55.

  • Market Realist6 months ago

    Transcatheter Heart Valve Therapy: Growth Driver for Edwards Lifesciences

    In 2Q17, Edwards Lifesciences’ (EW) Transcatheter Heart Valve Therapy segment reported revenues close to $316 million, which represents year-over-year growth of ~28%.

  • ETF.com6 months ago

    2017's Stock Market Can't Get Stranger

    What's been unusual about this year's market ascent is not how much stocks have risen. A gain of 12% for the SPDR S&P 500 ETF (SPY) through seven months of the year, while impressive, is well within historical norms. Rather, it's been the consistency and uniformity of the rally that has caught everyone off guard. In the ETF world, an investor could almost throw a dart and come up with gains. Everything from mega-caps to large-caps to midcaps to small-caps is up.   

  • Zacks6 months ago

    Will Low Cost ETF Strength Make Vanguard Top Asset Manager Soon?

    Can Vanguard dethrone BlackRock with the help of its low-cost funds and take the seat of the top asset manager?

  • Top Mid-Cap Blend ETFs
    Motley Fool6 months ago

    Top Mid-Cap Blend ETFs

    These mid-cap blend ETFs offer a low-cost way to own a diverse portfolio of mid-cap stocks. Here's how to find the right fit for your portfolio.

  • Shining The Transparency Light On ETFs
    ETF.com8 months ago

    Shining The Transparency Light On ETFs

    Taking advantage of one of the greatest benefits of ETFs—transparency—can lead to some surprising discoveries. Case in point: the world of small-cap ETFs. We’ve discovered that while a number of ETFs call themselves “small-caps,” they really don't have that much small-cap exposure. And that matters, because a fund that isn’t exactly small-cap is going to deliver different risks and different returns than a pure small-cap strategy. Clarifying Terms

  • Market Realist9 months ago

    Centene Saw Robust Rise in Medicaid Enrollments in 1Q17

    In 1Q17, around 12.1 million members were enrolled in Centene's (CNC) various healthcare plans, which is a year-over-year (or YoY) rise of around 600,000 beneficiaries.

  • Market Realist9 months ago

    Quest Diagnostics Could Get Greater Share of Laboratory Segment

    With around 50.0% of hospitals being served by Quest Diagnostics (DGX), the company has become a leading player in the fragmented US laboratory market.

  • Investopedia9 months ago

    Bigger is Better, But Small is Beautiful

    There is an ETF for every market cap appetite. Consider these to remain diversified with minimal fees.

  • Benzinga10 months ago

    Investors Back Away From Mid-Cap ETFs

    Broadly speaking, exchange-traded funds have been on a torrid pace of asset gathering through the first quarter, but there have recently been some signs of departures from large-cap equity funds. Data ...

  • Market Realistlast year

    Ball Corporation Declared Dividend of $0.13 per Share

    Ball Corporation declared a cash dividend of $0.13 per share on its common stock. It will be paid on March 15 to shareholders of record as of March 1, 2017.